Back to Quality Research
KEQUKewaunee Scientific Corporation
Health Care · Medical Specialities · Micro
$32.79+1.27%
As of 23 Oct 2026Mkt cap $104M
Stage 13
AVOID
Fundamentals
49.5/75
Technical
5.0/15
Independent
54.5/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −4.3%
- 3M
- −7.9%
- 6M
- −11.4%
- 1Y
- −24.1%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 10.2xHist median 9.0x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 6.7x
- FCF yield
- 15.0%
Quality
- ROIC
- 13.3%
- Operating margin
- 7.4%
- FCF margin
- 5.2%
- Current ratio
- 2.2x
Growth
- Revenue growth
- +17.3%Latest FY YoY
- Revenue CAGR
- +13.7%
- EPS CAGR
- −29.0%
- FCF CAGR
- −1.6%
Capital
- Share-count trend
- +0.8%3Y annualised
- Net debt
- $15M0.8x OCF
Annual trend
- CAGR 2022–2026
- +13.7%
- Latest · 2026
- $0B
- YoY
- +17.3%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
Which timing read is better supported as new price and operating evidence arrives: production v2 or research v3?
Watch next
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded